cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1619Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWКлиническая эффективность триметазидина как основного сердечно-сосудистого препарата метаболического действияClinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic actionГаспарянА. Ю.GasparyanA. Yu.a.gasparyan@gmail.ruПетросянА. Г.PetrosyanA. H.a.gasparyan@gmail.ruАйвазянЛ. М.AyvazyanL. M.a.gasparyan@gmail.ruЕреванский государственный медицинский университет им. М.Гераци, г. ЕреванM. Heratsi Yerevan State Medical University. Yerevan20082008200874101106Copyright © Гаспарян А.Ю., Петросян А.Г., Айвазян Л.М., 20082008Гаспарян А.Ю., Петросян А.Г., Айвазян Л.М.Gasparyan A.Y., Petrosyan A.H., Ayvazyan L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1619триметазидин3-кетоацил-коэнзим А тиолазаишемическая болезнь сердцасердечная недостаточностьлечениеэффективностьtrimetazidine3-ketoacyl-coenzyme A thiolasecoronary artery diseaseheart failuretreatmenteffectivenessReferencesHorowitz J.D., Sia S.T., Macdonald P.S., et al. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 1986; 13(2): 219-29.Horowitz J.D., Sia S.T., Macdonald P.S., et al. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 1986; 13(2): 219-29.Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: aChaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: aWolff A.A. The MARISA Investigators and CV Therapeutics. MARISA: Monotherapy Assessment of Ranolazine in Stable Angina. JACC 2000; 35(Suppl. A): 408 A.Wolff A.A. The MARISA Investigators and CV Therapeutics. MARISA: Monotherapy Assessment of Ranolazine in Stable Angina. JACC 2000; 35(Suppl. A): 408 A.Schmidt-Schweda S., Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000; 99(1): 27-35.Schmidt-Schweda S., Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000; 99(1): 27-35.Глезер М.Г., Асташкин Е.И. Предуктал -новое направление в цитопротекции миокарда. Клин геронт 1998; 1: 1-11.Глезер М.Г., Асташкин Е.И. Предуктал -новое направление в цитопротекции миокарда. Клин геронт 1998; 1: 1-11.Сыркин А.Л., Долецкий А. А.Триметазидин в лечении ишемической болезни сердца. Клинфармак тер 2001; 10(1): 1-4.Сыркин А.Л., Долецкий А. А.Триметазидин в лечении ишемической болезни сердца. Клинфармак тер 2001; 10(1): 1-4.Шабалин А.В., Никитин Ю.П. Защита кардиомиоцита. Современное состояние и перспективы. Кардиология 1999; 29(3): 4-10.Шабалин А.В., Никитин Ю.П. Защита кардиомиоцита. Современное состояние и перспективы. Кардиология 1999; 29(3): 4-10.Lopaschuk G.D. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998; 82(5A): 14K-7.Lopaschuk G.D. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998; 82(5A): 14K-7.Kantor P.F., Lucien A., Kozak R., et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. J Circ Res 2000; 86(5): 580-8.Kantor P.F., Lucien A., Kozak R., et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. J Circ Res 2000; 86(5): 580-8.de Leiris J., Boucher F. Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome. Eur Heart J 1993; 14Suppl G: 34-40.de Leiris J., Boucher F. Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome. Eur Heart J 1993; 14Suppl G: 34-40.Sentex E, Sergiel JP, Lucien A, et al. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997; 175: 153-62.Sentex E, Sergiel JP, Lucien A, et al. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997; 175: 153-62.Ruiz Meana M, Garcia Dorado D, Julia M, et al. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovasc Res 1996; 32: 587-92.Ruiz Meana M, Garcia Dorado D, Julia M, et al. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovasc Res 1996; 32: 587-92.Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949-58.Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949-58.Devynck MA, Le Quan Sang KH, Joulin Y, et al. Acute membrane effects of trimetazidine in human platelets. Eur J Pharmacol 1993; 245: 105-10.Devynck MA, Le Quan Sang KH, Joulin Y, et al. Acute membrane effects of trimetazidine in human platelets. Eur J Pharmacol 1993; 245: 105-10.Astarie-Dequeker C, Joulin Y, Devynck MA. Inhibitory effect of trimetazidine on thrombin-induced aggregation and calcium entry into human platelets. J Cardiovasc Pharmacol 1994; 23: 401-7.Astarie-Dequeker C, Joulin Y, Devynck MA. Inhibitory effect of trimetazidine on thrombin-induced aggregation and calcium entry into human platelets. J Cardiovasc Pharmacol 1994; 23: 401-7.Willoughby SR, Chirkov YY, Kennedy JA, et al. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol 1998; 207-13.Willoughby SR, Chirkov YY, Kennedy JA, et al. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol 1998; 207-13.Kowalski J, Pawlicki L, Baj Z, et al. Effect of trimetazidine on biological activity of neutrophils in patients with transient myocardial ischemia induced by exercise testing. Pol Merkuriusz Lek 2000; 9: 548-51.Kowalski J, Pawlicki L, Baj Z, et al. Effect of trimetazidine on biological activity of neutrophils in patients with transient myocardial ischemia induced by exercise testing. Pol Merkuriusz Lek 2000; 9: 548-51.Kajstura J, Liu Y, Baldini A, et al. Coronary artery constriction in rats: necrotic and apoptotic myocyte death. Am J Cardiol 1998; 82(5A): 30K-41.Kajstura J, Liu Y, Baldini A, et al. Coronary artery constriction in rats: necrotic and apoptotic myocyte death. Am J Cardiol 1998; 82(5A): 30K-41.Goupit P. Pharmacocinйtique de la trimйtazidine. Concours Med 1987; 109(Suppl 36): 3447-51.Goupit P. Pharmacocinйtique de la trimйtazidine. Concours Med 1987; 109(Suppl 36): 3447-51.Harpey C, Clauser P, Labrid C, et al. Trimetazidine: a cellular anti-ischemic agent. Cardiovasc Drug Rev 1989; 6(4): 292-312.Harpey C, Clauser P, Labrid C, et al. Trimetazidine: a cellular anti-ischemic agent. Cardiovasc Drug Rev 1989; 6(4): 292-312.Edeki TI, Johnston A, Campbell DB, et al. An examination of the possible pharmacokinetic interaction of trimetazidine with theophylline, digoxin and antipyrine. Br J Clin Pharmacol 1989; 26: 657.Edeki TI, Johnston A, Campbell DB, et al. An examination of the possible pharmacokinetic interaction of trimetazidine with theophylline, digoxin and antipyrine. Br J Clin Pharmacol 1989; 26: 657.Simon N, Brunet P, Roumenov D, et al. Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients. Br J Clin Pharmacol 1997; 44: 591-4.Simon N, Brunet P, Roumenov D, et al. Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients. Br J Clin Pharmacol 1997; 44: 591-4.Passeron J. Efficacite de la trimetazidine dans I’angor d’effort stable de l’insuffisant coronarien chronique. Etude а double insu contre placebo. Presse Med 1986; 15: 1775-8.Passeron J. Efficacite de la trimetazidine dans I’angor d’effort stable de l’insuffisant coronarien chronique. Etude а double insu contre placebo. Presse Med 1986; 15: 1775-8.Sellier P, Audouin P, Payen B, et al. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 1987; 33: 205-7.Sellier P, Audouin P, Payen B, et al. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 1987; 33: 205-7.Sellier P, Audouin P, Payen B, et al. Effets ergomйtriques d’une administration unique de trimйtazidine. Presse Med 1986; 15: 1771-4.Sellier P, Audouin P, Payen B, et al. Effets ergomйtriques d’une administration unique de trimйtazidine. Presse Med 1986; 15: 1771-4.Michaelides AP, Vyssoulis GR, Bonoris PE, et al. Beneficial effects of trimetazidine in men with stable angina under betablocker treatment. Curr Ther Res 1989; 46: 565-76.Michaelides AP, Vyssoulis GR, Bonoris PE, et al. Beneficial effects of trimetazidine in men with stable angina under betablocker treatment. Curr Ther Res 1989; 46: 565-76.Lu C, Dabrowski P, Fragasso G, et al. Effects of trimetazidine on ichemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.Lu C, Dabrowski P, Fragasso G, et al. Effects of trimetazidine on ichemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.Detry L, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279- 88.Detry L, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279- 88.Detry L, Leclerc P. On behalf of the Trimetazidine European Multicenter Study Group. Trimetazidine European multicenter study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995; 76: 813.Detry L, Leclerc P. On behalf of the Trimetazidine European Multicenter Study Group. Trimetazidine European multicenter study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995; 76: 813.Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. J Cardiovasc Drugs Ther 1990; 4(Suppl 4): 853-9.Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. J Cardiovasc Drugs Ther 1990; 4(Suppl 4): 853-9.Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-7.Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-7.Szwed H, Pachocki R, Domzal-Bochenska M, et al. Efficacitй et tolйrance de la trimйtazidine, antiangoreux mйtabolique, en association avec un antiangoreux hйmodynamique dans l’angor d’effort stable. TRIMPOL I une йtude multicentrique. Presse Med 2000; 29: 533-8.Szwed H, Pachocki R, Domzal-Bochenska M, et al. Efficacitй et tolйrance de la trimйtazidine, antiangoreux mйtabolique, en association avec un antiangoreux hйmodynamique dans l’angor d’effort stable. TRIMPOL I une йtude multicentrique. Presse Med 2000; 29: 533-8.Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22(24): 2267- 74.Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22(24): 2267- 74.Куимов А.Д., Маянская С.Д., Лукша Е.Б. и др. Влияние терапии триметазидином на толерантность к физической нагрузке и диастолическую функцию левого желудочка сердца у больных ишемической болезнью сердца. Тер архив 1999; 71(1): 39-42.Куимов А.Д., Маянская С.Д., Лукша Е.Б. и др. Влияние терапии триметазидином на толерантность к физической нагрузке и диастолическую функцию левого желудочка сердца у больных ишемической болезнью сердца. Тер архив 1999; 71(1): 39-42.Effect of 48-h intravenous trimetazidine on short– and longterm outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebocontrolled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project-Free Radicals. Eur Heart J 2000; 21: 1537-46.Effect of 48-h intravenous trimetazidine on short– and longterm outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebocontrolled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project-Free Radicals. Eur Heart J 2000; 21: 1537-46.Di Pasquale P, Lo Verso P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. J Cardiovasc Drugs Ther 1999; 13: 423-8.Di Pasquale P, Lo Verso P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. J Cardiovasc Drugs Ther 1999; 13: 423-8.Papadopoulos CL, Kanonidis IE, Kotridis PS, et al. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Int J Cardiol 1996; 55: 137-42.Papadopoulos CL, Kanonidis IE, Kotridis PS, et al. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Int J Cardiol 1996; 55: 137-42.Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.Недошивин А.О., Кутузова А.Э., Нестерова И.В. и др. Триметазидин в коррекции хронической сердечной недостаточности у больных ишемической болезнью сердца Кардиология 2002; 3: 12-5.Недошивин А.О., Кутузова А.Э., Нестерова И.В. и др. Триметазидин в коррекции хронической сердечной недостаточности у больных ишемической болезнью сердца Кардиология 2002; 3: 12-5.Belardinelli R. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 2000; 19(Suppl 5): V35-9.Belardinelli R. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 2000; 19(Suppl 5): V35-9.Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 1992; 33: 486-91.Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 1992; 33: 486-91.Tunerir B, Colak O, Alata O, et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999; 68: 2173-6.Tunerir B, Colak O, Alata O, et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999; 68: 2173-6.Vedrinne JM, Vedrinne C, Bompard D, et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, doubleblind, placebo-controlled study with trimetazidine. Anesth Analg 1996; 82: 712-8.Vedrinne JM, Vedrinne C, Bompard D, et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, doubleblind, placebo-controlled study with trimetazidine. Anesth Analg 1996; 82: 712-8.Szwed H, Sadowski Z, Pachocki R, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. J Cardiovasc Drugs Ther 1999; 13: 217-22.Szwed H, Sadowski Z, Pachocki R, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. J Cardiovasc Drugs Ther 1999; 13: 217-22.Wierzbicki P, Cwetsch A, Fijakowski P, et al. Influence of trimetazidine on echocardiography parameters and free radical stress index in coronary artery disease and end-stage renal failure patients treated by hemodialysis: preliminary communication. Pol Arch Med Wewn 1999; 102: 589-94.Wierzbicki P, Cwetsch A, Fijakowski P, et al. Influence of trimetazidine on echocardiography parameters and free radical stress index in coronary artery disease and end-stage renal failure patients treated by hemodialysis: preliminary communication. Pol Arch Med Wewn 1999; 102: 589-94.Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, doubleblind, placebo-controlled study. Am J Cardiovasc Drugs 2003; 3: 361-9.Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, doubleblind, placebo-controlled study. Am J Cardiovasc Drugs 2003; 3: 361-9.Napoli PD, Giovanni PD, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and Reduction in Mortality and Hospitalization in Patients With Ischemic Dilated Cardiomyopathy: A Post Hoc Analysis of the Villa Pini D'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50:585-589.Napoli PD, Giovanni PD, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and Reduction in Mortality and Hospitalization in Patients With Ischemic Dilated Cardiomyopathy: A Post Hoc Analysis of the Villa Pini D'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50:585-589.
The authors declare that there are no conflicts of interest present.